Phase 2 Trial of Brigatinib after Treatment with Second-Generation ALK inhibitors in Refractory ALK Rearranged NSCLC
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Millennium Pharmaceuticals, Inc.
Start Date
February 15, 2017
End Date
September 8, 2022
Administered By
Duke Cancer Institute
Awarded By
Millennium Pharmaceuticals, Inc.
Start Date
February 15, 2017
End Date
September 8, 2022